COMPANY:

TGen

" Soteria Precision Medicine Foundation...today announced a partnership with the Translational Genomics Research Institute (TGen), part of City of Hope, to provide precision medicine navigation for Special Operation Forces in their battle against cancer."

"An unprecedented effort to sequence the genome, exome and RNA in tumors from patients with multiple myeloma defines distinct subtypes of the disease, according to an international team of scientists led by researchers from the Translational Genomics Research Institute (TGen)."

"Researchers at City of Hope...and Translational Genomics Research Institute (TGen)...have developed and tested an innovative machine-learning approach that could one day enable the earlier detection of cancer in patients by using smaller blood draws. The study was published today in the journal Science Translational Medicine."

"City of Hope...and TGe...has been awarded $4.5 million to validate a liquid biopsy for the early detection of pancreatic cancer. The blood-based diagnostic developed by the National Cancer Institute’s Pancreatic Cancer Detection Consortium (PCDC) leverages exosomal microRNAs that serve as a biomarker or unique RNA fingerprint for the early detection of disease or recurrence."

"A team of researchers including faculty at the Translational Genomics Research Institute (TGen), part of City of Hope, published a study that combines genomics and machine learning in the quest to make early detection of cancer more affordable and widely available...Published this week in Science Translational Medicine, researchers used a machine-learning model to identify DNA fragments in blood plasma shed by cancer cells. The technique uses readily available lab materials, and it detected cancers at an early stage among nearly all of the samples they studied."

"Nautilus Biotechnology, Inc...and the Translational Genomics Research Institute (TGen)...announced a partnership to explore the utility of the Nautilus platform by studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often fatal childhood cancer. The goal of the partnership between Nautilus and TGen is to better understand the epigenetic mechanisms at work in DIPG by interrogating the proteoform landscape of specific proteins at the single-molecule level. In doing so, TGen plans to explore the combination of alterations and modifications present on these proteins (proteoforms) that are not possible to detect by peptide-based protein analysis methods....This collaboration represents the fifth early collaboration program for Nautilus as it advances towards broader platform access in 2023 and commercial launch in 2024....The partnership will commence in early 2023 and the team intends to publish its findings once the study is completed."

"Tumor DNA circulating in the bloodstream can help clinicians decide whether chemotherapy is right for their patients who have undergone surgery for stage II colon cancer, according to a breakthrough study published online in The New England Journal of Medicine and presented today at the 2022 American Society of Clinical Oncology Annual Meeting (Abstract LBA100). An international team that included investigators from the Translational Genomics Research Institute (TGen), part of City of Hope, conducted the study to lend clarity to the role of adjuvant chemotherapy in this setting...A total of 455 patients in Australian centers were assigned to either ctDNA-guided care (n=302) or standard care (n=153) following their surgeries. Standard care follows traditional guidelines based on clinicopathological features that are associated with higher cancer risk. If patients in the study’s guided group still had ctDNA present in their blood samples four to seven weeks..."